Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Span
- PDF / 1,020,869 Bytes
- 19 Pages / 595.276 x 790.866 pts Page_size
- 17 Downloads / 163 Views
ORIGINAL RESEARCH
Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting Virginia Martı´n . Josep Vidal . Samuel J. P. Malkin . Nino Halle´n . Barnaby Hunt
Received: June 16, 2020 Ó The Author(s) 2020
ABSTRACT Introduction: Healthcare systems aim to maximize the health of the population, but must work within constrained budgets. Therefore, choosing therapies that are both effective and cost-effective is paramount. The present analysis assessed the cost-effectiveness of onceweekly semaglutide 0.5 mg and 1 mg versus once-weekly dulaglutide 1.5 mg and versus Digital Features To view digital features for this article go to https://doi.org/10.6084/m9.figshare.12745430. Electronic Supplementary Material The online version of this article (https://doi.org/10.1007/s12325020-01464-1) contains supplementary material, which is available to authorized users. V. Martı´n Novo Nordisk Pharma SA, Madrid, Spain J. Vidal Endocrinology and Nutrition Department, Hospital Clı´nic, Barcelona, Spain J. Vidal Centro de Investigacio´n Biome´dica en Red en Diabetes y Enfermedades Metabo´licas Asociadas (CIBERDEM), Barcelona, Spain S. J. P. Malkin B. Hunt (&) Ossian Health Economics and Communications, Basel, Switzerland e-mail: [email protected] N. Halle´n Novo Nordisk A/S, Søborg, Denmark
once daily sitagliptin 100 mg for the treatment of patients with type 2 diabetes with inadequate glycemic control on oral anti-hyperglycemic medications over patient lifetimes from a healthcare payer perspective in the Spanish setting. Methods: Cost and clinical outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model. Baseline cohort characteristics and treatment effects on initiation of semaglutide 0.5 mg and 1 mg, dulaglutide 1.5 mg and sitagliptin 100 mg were based on the once-weekly semaglutide clinical trial program (SUSTAIN 7 and 2). Captured costs included treatment costs and costs of diabetesrelated complications. Projected outcomes were discounted at 3.0% annually. Results: Projections of long-term clinical outcomes indicated that once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in discounted life expectancy of 0.02 and 0.11 years, respectively, and discounted quality-adjusted life expectancy of 0.03 and 0.11 quality-adjusted life years (QALYs), respectively, versus dulaglutide 1.5 mg. Compared with sitagliptin, once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in discounted life expectancy of 0.17 and 0.24 years, respectively and discounted quality-adjusted life expectancy of 0.16 and 0.23 QALYs. The increased duration and quality of life with once-weekly semaglutide 0.5 mg and 1 mg resulted from a reduced cumulative
Adv Ther
incidence and delayed time to onset of diabetesrelated complications. Avoided complications resulted in once-weekly semaglutide 0.5 mg and 1 mg being cost-saving versus dulaglutide 1.5 mg and versus sitagliptin 100 mg from a healthcare payer perspective. Co
Data Loading...
